Frank's Tea Party Revolt

[orlander_file]

Radondoc's post on Mondays information
Re: Dendreon's Provenge at AACR's 2007 Annual Meeting - Monday, 16 April.
Anybody who doesn't believe in the long term potential of Provenge has not read this most recent abstract to be presented at the 2007 AACR Annual Meeting this Monday. Two points that strike me the most: 1) Immune monitoring was obtained prior to booster at a median 21 months in the Provenge arm vs. 8 months in the placebo arm. This implies that placebo patients failed biochemically 13 months earlier than Provenge patients before they were eligible for booster Provenge or placebo. 2) The immune stimulation index more than doulbed when compared before Provenge booster to 13 weeks post booster. These 2 important points suggest that Provenge can prolong the time to biochemical failure in ADPCa which likely can delay the time to clinical progression, and booster Provenge can boost the immune response even higher which likely will produce a more profound clinical effect. These most recent P-11 results add further evidence in my belief that Provenge can become the highest selling oncology drug of all time. Cannot wait for further P-11 results at either this years ASCO or AUA meeting.

Good luck to all longs and prostate cancer patients.